Anavex Life Sciences Corp.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $7.8M | $-5.3M | $-5.7M | $-9.8M | $-13.2M | $-11.2M | $-12.1M | $-11.6M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $-17.1M | $314.0K | $1.1M | $3.7M | $4.3M | $1.4M | $2.1M | $2.0M |
| Net Cash from Operating Activities | $-9.1M | $-4.4M | $-7.2M | $-8.6M | $-12.5M | $-5.9M | $-12.1M | $-6.7M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $0 | $113.0K | $36.3M | $10.0M | $-2.1M | $852.0K | $708.0K | $89.0K |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | — | — |